Navigation Links
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
Date:9/17/2011

THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in bone mineral density (BMD), an important determinant of bone strength, and a persistent reduction in markers of bone turnover. The data were presented at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego.

Results of the Phase 2 study extension showed that for postmenopausal women with low bone mass or osteoporosis who received up to eight years of continued treatment with Prolia, BMD at the lumbar spine and total hip increased on average by 16.8 percent and 6.9 percent as compared to baseline, respectively.  The overall adverse event profile is consistent with events previously reported.

"We don't yet have a cure for osteoporosis, and many postmenopausal women with this condition who are at high risk for fractures require long-term therapy for this serious disease," said lead author Michael McClung, M.D., founding director, Oregon Osteoporosis Center. "This study provides additional data that Prolia continues to increase bone mineral density progressively over a treatment period of eight years. This study supports the long-term clinical experience of Prolia for women with this chronic condition."

This Phase 2 study extension sought to determine the effects of up to eight years of continued treatment with Prolia on BMD and bone turnover markers in postmenopausal women with low bone mass or osteoporosis.

In the original Phase 2 dose-ranging trial for Prolia, 412 postmenopausal women with a BMD T-score (amount of matter per cubic centimeter of bones) between -1.8 and -4.0 (lumbar spine) and/or -1.8 and -3.5 (total hip or femoral ne
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
2. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
3. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
4. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
5. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
6. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
9. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
10. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
11. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- According to the new research ... Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, Musculoskeletal) ... Forecast to 2019" published by MarketsandMarkets, the global Physiotherapy ... by 2019 from $14,240.0 Million in 2014, at ... Browse 74 market data tables and ...
(Date:9/19/2014)... , Sept. 19, 2014 Research and Markets ... Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - ... For the purposes of this report, the human microbiome market ... The human microbiome market is expected to be valued as ... a CAGR of 22.3% within the forecast period of 2019-2023. ...
(Date:9/19/2014)... , Sept. 19, 2014  Diplomat, the nation,s ... David Dreyer to the Board of Directors ... director and will also serve as chair of the ... 30 years of accounting, financial, compliance and operating experience ... Dreyer has served as chief financial officer, chief operating ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3David Dreyer Appointed to Diplomat Board of Directors 2
... June 9, 2011 Dr. Lowell S. Kabnick, MD, RPhS, ... authority and pioneer in the field of vascular surgery, is ... first in the country to use the new VenaCure® 1470nm ... lower power output compared with other lasers resulting in effective ...
... June 9, 2011 GeNO LLC ( www.genollc.com ), ... it has been awarded a new patent for its ... GeNO,s seventh patent, concerns a method of providing a ... in a manner that converts nitrogen dioxide (NO2) to ...
Cached Medicine Technology:Dr. Lowell S. Kabnick First to Use New VenaCure® 1470nm Laser 2GeNO LLC Announces New Patent for Nitric Oxide Delivery System 2
(Date:9/20/2014)... (HealthDay News) -- As flu season approaches, the best ... get a flu shot and a checkup, according to ... doctor can vaccinate people against the flu, and also ... Retail stores may provide flu shots for their customers, ... Jorge Parada, medical director of infection prevention and control ...
(Date:9/20/2014)... 20, 2014 As concerns surrounding ... in gynecological surgeries continue to grow, Bernstein ... announced plans to end coverage for uterine morcellation. ... last month, Harrisburg, Pennsylvania-based Capital BlueCross will end ... The insurer said its decision was prompted by ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking coffee ... is re-visiting that advice and changing his stance after considering ... have on oral health. “There’s good news and great news,” ... beneficial in protecting against gum disease, and red wine can ... was from the September 2014 issue of Boston University ...
(Date:9/20/2014)... 20, 2014 Earlier this week, Home Depot ... have had their credit card information pilfered by hackers, surpassing ... slew of headline articles like this one published ... eye opening numbers. , “Most people tend to focus ... it’s a way to score a game,” says Joe Caruso, ...
(Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
Breaking Medicine News(10 mins):Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... Inc. (NYSE Alternext: DDD) today announced that Daniel O. Wilds had ... member of its Board of Directors effective December 12, 2008. ... of the Board of SCOLR Pharma, said, "On behalf of the ... thank Dan for his more than five years of vision and ...
... CareTech Solutions, an information,technology (IT) and Web products and ... it has won a coveted 2008 Best in KLAS,award ... by,healthcare executives and professionals in the 2008 Top 20 ... , "As economic ...
... virus can reach immune cells in just 4 hours , , ... male-to-female transmission of HIV -- in which the virus can ... just four hours -- has been identified by U.S. researchers. ... the vaginal tract was an effective barrier to HIV during ...
... -- China Sky One,Medical, Inc. ("China Sky One ... ), a,leading fully integrated pharmaceutical company producing over-the-counter,drugs ... today that it,successfully obtained the production approval from ... for two additional drugs: Sodium Cromoglicate,Eye Drops for ...
... Mountains Re Ltd., the reinsurance unit of White Mountains Insurance Group, ... Chief Financial Officer, will retire from full-time work at the end ... assessment advisor to White Mountains. , , ... "Over the last 7 years Chuck has filled many roles within ...
... PITTSBURGH, Dec. 16 MED3OOO, Inc., a national healthcare management, ... able to help the City of Newark, Ohio recover lost ... companies. , , After partnering ... of Newark Division Fire & EMS department is now able ...
Cached Medicine News:Health News:SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds 2Health News:CareTech Solutions Named 'Best in KLAS' for Extensive IT Outsourcing Services 2Health News:HIV Can Penetrate a Woman's Healthy Genital Skin 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs 3Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 2Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 3Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 4Health News:City of Newark, Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 2Health News:City of Newark, Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 3
The Spinchron 15 centrifuge provides all the versatility and high capacity needed for today's full-service clinical lab needs. This centrifuge is available in a nonrefrigerated model with a speed up ...
... a simple click of the mouse ... mouse cursor to the desired position ... slide and the magnified image is ... Interface (GUI) enables one-click operation of ...
The simplest, neatest, most efficient anti-theft system for frames and sunwear. Available in 3 colors Black, Matte aluminum, and Bronze. Fits with any style or color of furniture. Safe, simple, easy...
Counter top frosted acrylic 4 frame display....
Medicine Products: